Home>Topics>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb BMY

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Bristol - Myers says hepatitis C drug combination succeeds in study

      Headlines

      Sat, 25 Apr 2015

      April 25 (Reuters) - Bristol - Myers Squibb Co said its experimental drug cured hepatitis C in over 90 percent of patients in combination with Gilead Sciences Inc's Sovaldi and a commonly prescribed...

    2. UPDATE 1- Bristol wins EU green light for immune system cancer drug

      Headlines

      Fri, 24 Apr 2015

      LONDON, April 24 (Reuters) - European regulators have recommended approval of Bristol - Myers Squibb 's Opdivo, paving the way for it to become the first of a closely watched group of immune system-boosting cancer medicines to go on sale in Europe.

    3. EU regulators warn against combining hep C drugs with amiodarone

      Headlines

      Fri, 24 Apr 2015

      April 24 (Reuters) - European health regulators warned on Friday against using Gilead Sciences Inc's and Bristol - Myers Squibb Co 's hepatitis C medicines along with amiodarone, a drug used to regulate the heartbeat of people with heart rhythm disorders.

    4. BRIEF-EU medicines agency backs Bristol Myers Squibb's melanoma drug

      Headlines

      Fri, 24 Apr 2015

      * Recommends approval of melanoma drug nivolumab from Bristol - Myers Squibb Co

    5. Bristol wins EU green light for immune system cancer drug

      Headlines

      Fri, 24 Apr 2015

      LONDON, April 24 (Reuters) - European regulators have recommended approval of Bristol - Myers Squibb 's Opdivo, paving the way for it to become the first of a closely watched group of immune system-boosting cancer medicines to go on sale in Europe.

    6. Bristol - Myers immunotherapy combo promising in melanoma-study

      Headlines

      Mon, 20 Apr 2015

      April 20 (Reuters) - A combination of two Bristol - Myers Squibb drugs that help the immune system fight melanoma led to significantly greater tumor shrinkage than treatment with one of the medicines, according to a midstage study presented on Monday.

    7. Merck Reports Strong Keytruda Data, Supporting Our Above-Consensus Expectations

      Commentary

      Mon, 20 Apr 2015

      consensus of $4 billion. Merck and Bristol - Myers Squibb are creating first-mover advantages ..... Keytruda showed in melanoma relative to Bristol 's cancer drug Yervoy is likely ..... a first-line drug. However, Bristol 's Checkmate 059 study of Yervoy

    8. UPDATE 2- Bristol's Opdivo proves effective against second type of lung cancer

      Headlines

      Fri, 17 Apr 2015

      April 17 (Reuters) - A large study of Bristol - Myers Squibb Co 's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said,...

    9. Bristol's Opdivo proves effective against second type of lung cancer

      Headlines

      Fri, 17 Apr 2015

      April 17 (Reuters) - A large study of Bristol - Myers Squibb Co 's Opdivo treatment has been halted after proving the drug is effective against a common form of lung cancer, the company said

    10. Bristol's Strong Efficacy in Lung Cancer Study Supports Our Above-Consensus Projections for Opdivo

      Commentary

      Fri, 17 Apr 2015

      Bristol Myers - Squibb 's announcement that it is ending its ..... Drug Administration in mid-2015. While Bristol already gained U.S. approval for squamous ..... because of an improved survival benefit, Bristol is ending the study to allow patients

    « Prev12345Next »
    Content Partners